GenFleet (2595) Included in Key Hang Seng and MSCI Indices

Bulletin Express

Feb 13

GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 2595) announced that it will be added to multiple Hang Seng Index Series and the MSCI Global Small Cap Index. According to the quarter-end review by Hang Seng Indexes Company Limited on February 13, 2026, GenFleet is set to join the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Hong Kong Index, and Hang Seng Innovative Drug Index, among others, effective March 9, 2026. The inclusion in the MSCI Global Small Cap Index takes effect after the close of trading on February 27, 2026.

GenFleet’s shares will also be included in additional Hang Seng sub-indices, such as the Hang Seng Composite MidCap & SmallCap Index, Hang Seng Composite SmallCap Index, Hang Seng SCHK Mainland China Companies Index, and other related healthcare and innovative drug indices. The Hang Seng Composite Index covers the top 95% of listed companies by cumulative market capitalization on the HKEX Main Board.

The board of directors states that entering multiple benchmark indices underscores recognition of the company’s ongoing value and growth potential, potentially increasing share liquidity and diversifying its investor base. GenFleet focuses on RAS-targeted therapeutics as part of its pipeline in oncology and autoimmune diseases. It leverages an integrated research and development platform—from target discovery to manufacturing—to advance treatments for unmet medical needs. The company’s approach includes novel molecular modalities and explorations of clinical development routes to capture significant market opportunities in China and globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1171806203"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171806203\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171806203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171806203","market":"us","top_or_hot":-1,"title":"GenFleet (2595) Included in Key Hang Seng and MSCI Indices","media":"Bulletin Express","content":"<p>GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 2595) announced that it will be added to multiple Hang Seng Index Series and the MSCI Global Small Cap Index. According to the quarter-end review by Hang Seng Indexes Company Limited on February 13, 2026, GenFleet is set to join the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Hong Kong Index, and Hang Seng Innovative Drug Index, among others, effective March 9, 2026. The inclusion in the MSCI Global Small Cap Index takes effect after the close of trading on February 27, 2026.</p>\n<p>GenFleet’s shares will also be included in additional Hang Seng sub-indices, such as the Hang Seng Composite MidCap & SmallCap Index, Hang Seng Composite SmallCap Index, Hang Seng SCHK Mainland China Companies Index, and other related healthcare and innovative drug indices. The Hang Seng Composite Index covers the top 95% of listed companies by cumulative market capitalization on the HKEX Main Board.</p>\n<p>The board of directors states that entering multiple benchmark indices underscores recognition of the company’s ongoing value and growth potential, potentially increasing share liquidity and diversifying its investor base. GenFleet focuses on RAS-targeted therapeutics as part of its pipeline in oncology and autoimmune diseases. It leverages an integrated research and development platform—from target discovery to manufacturing—to advance treatments for unmet medical needs. The company’s approach includes novel molecular modalities and explorations of clinical development routes to capture significant market opportunities in China and globally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenFleet (2595) Included in Key Hang Seng and MSCI Indices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenFleet (2595) Included in Key Hang Seng and MSCI Indices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-13 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 2595) announced that it will be added to multiple Hang Seng Index Series and the MSCI Global Small Cap Index. According to the quarter-end review by Hang Seng Indexes Company Limited on February 13, 2026, GenFleet is set to join the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Hong Kong Index, and Hang Seng Innovative Drug Index, among others, effective March 9, 2026. The inclusion in the MSCI Global Small Cap Index takes effect after the close of trading on February 27, 2026.</p>\n<p>GenFleet’s shares will also be included in additional Hang Seng sub-indices, such as the Hang Seng Composite MidCap & SmallCap Index, Hang Seng Composite SmallCap Index, Hang Seng SCHK Mainland China Companies Index, and other related healthcare and innovative drug indices. The Hang Seng Composite Index covers the top 95% of listed companies by cumulative market capitalization on the HKEX Main Board.</p>\n<p>The board of directors states that entering multiple benchmark indices underscores recognition of the company’s ongoing value and growth potential, potentially increasing share liquidity and diversifying its investor base. GenFleet focuses on RAS-targeted therapeutics as part of its pipeline in oncology and autoimmune diseases. It leverages an integrated research and development platform—from target discovery to manufacturing—to advance treatments for unmet medical needs. The company’s approach includes novel molecular modalities and explorations of clinical development routes to capture significant market opportunities in China and globally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1171806203","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171806203","pubTimestamp":1770993919,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 2595) announced that it will be added to multiple Hang Seng Index Series and the MSCI Global Small Cap Index. According to the quarter-end review by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"GenFleet(2595)纳入主要恒生及MSCI指数","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 2595) announced that it will be added to multiple Hang Seng Index Series and the MSCI Global Small Cap Index. According to the quarter-end review by Hang Seng Indexes Company Limited on February 13, 2026, GenFleet is set to join the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Hong Kong Index, and Hang Seng Innovative Drug Index, among others, effective March 9, 2026. The inclusion in the MSCI Global Small Cap Index takes effect after the close of trading on February 27, 2026.\nGenFleet’s shares will also be included in additional Hang Seng sub-indices, such as the Hang Seng Composite MidCap & SmallCap Index, Hang Seng Composite SmallCap Index, Hang Seng SCHK Mainland China Companies Index, and other related healthcare and innovative drug indices. The Hang Seng Composite Index covers the top 95% of listed companies by cumulative market capitalization on the HKEX Main Board.\nThe board of directors states that entering multiple benchmark indices underscores recognition of the company’s ongoing value and growth potential, potentially increasing share liquidity and diversifying its investor base. GenFleet focuses on RAS-targeted therapeutics as part of its pipeline in oncology and autoimmune diseases. It leverages an integrated research and development platform—from target discovery to manufacturing—to advance treatments for unmet medical needs. The company’s approach includes novel molecular modalities and explorations of clinical development routes to capture significant market opportunities in China and globally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}